The Use of Angiotensin Receptor Blockers and the Risk of Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and
telmisartan in particular, are associated with an increased overall risk of the four most
common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective
was to explore these effects separately for each of the four cancers and in combination with
angiotensin-converting-enzyme-inhibitors (ACEIs).